KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Depreciation and Depletion: 2013-2025

Historic Depreciation and Depletion for Ionis Pharmaceuticals (IONS) over the last 13 years, with Sep 2025 value amounting to $2.3 million.

  • Ionis Pharmaceuticals' Depreciation and Depletion fell 4.49% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year decrease of 9.37%. This contributed to the annual value of $9.6 million for FY2024, which is 6.59% down from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Depreciation and Depletion stood at $2.3 million for Q3 2025, which was down 0.49% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Depreciation and Depletion registered a high of $4.0 million during Q2 2021, and its lowest value of $2.2 million during Q1 2025.
  • Moreover, its 3-year median value for Depreciation and Depletion was $2.5 million (2024), whereas its average is $2.4 million.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Depreciation and Depletion climbed by 29.01% in 2021 and then crashed by 33.90% in 2023.
  • Ionis Pharmaceuticals' Depreciation and Depletion (Quarterly) stood at $3.8 million in 2021, then decreased by 20.80% to $3.0 million in 2022, then dropped by 15.96% to $2.5 million in 2023, then decreased by 11.95% to $2.2 million in 2024, then declined by 4.49% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, $2.3 million for Q2 2025, and $2.2 million during Q1 2025.